We applied mass spectrometry with DIA quantification to identify biomarker candidates in CSF samples from a well-characterized cohort consisted of 20 SAH patients.
This dataset include the proteomic data of 243 glioma tumor tissues (discovery: 187, validation: 56); 56 tumor-adjacent tissues (discvoery: 35, validation: 21); 12 normal brain tissues; corresponding phosphoproteomic data